Related Experiment Video

Updated: Mar 8, 2026

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

16.6K

Ecrg4 contributes to the anti-glioma immunosurveillance through type-I interferon signaling

Tetsuo Moriguchi1, Shun Kaneumi2, Shuji Takeda3

  • 1Division of Stem Cell Biology, Institute for Genetic Medicine, Hokkaido University , Sapporo, Hokkaido, Japan.

Oncoimmunology
|January 27, 2017
PubMed

Insights

Esophageal cancer-related gene 4 (Ecrg4) enhances antitumor immunity. Ecrg4 promotes tumor suppression by activating type-I interferon signaling and T cell responses, suggesting its immunotherapy potential.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Esophageal cancer-related gene 4 (Ecrg4) is a peptide hormone implicated as a tumor suppressor.
  • The precise mechanisms by which Ecrg4 inhibits tumorigenesis remain largely unelucidated.

Purpose of the Study:

  • To investigate the role of Ecrg4 in tumor suppression and elucidate its underlying mechanisms.
  • To explore the potential of Ecrg4 as a target for cancer immunotherapy.

Main Methods:

  • Generation of Ecrg4-null and wild-type glioma-initiating cell (GIC) lines from Ecrg4 knockout mice.
  • Tumorigenicity assays in immunocompetent mice with selective depletion of immune cells (CD4+, CD8+, NK cells).
  • In vitro studies on Ecrg4 fragment-induced cytokine expression in microglia.
  • In vivo experiments involving blockade of type-I interferon (IFN) signaling.

Main Results:

  • Ecrg4-null GICs formed tumors, while wild-type GICs were eliminated by the host immune system, including T cell responses.
  • Depletion of CD4+, CD8+, or NK cells restored tumorigenicity of wild-type GICs.
  • Ecrg4 fragments induced pro-inflammatory cytokines in microglia.
  • Blockade of type-I IFN signaling abrogated Ecrg4-mediated antitumor activity.

Conclusions:

  • Ecrg4 possesses significant antitumor function by bolstering host immunity.
  • Ecrg4 enhances immunity through type-I IFN signaling and adaptive T cell responses.
  • Ecrg4 represents a promising clinical candidate for cancer immunotherapy.
Keywords:
Ecrg4gliomaimmunosurveillancemicrogliatype-I IFN

More Related Videos

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections05:45

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Published on: July 31, 2017

10.2K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.1K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K